Abstract: Over the past few years, rapid developments in omics technologies, including genomics, proteomics and metabolomics, have led them to be highly regarded in the field of biomedical research for the early detection and treatment of cancer. These technologies are of great value in exploring the mechanism of tumorigenesis and discovering novel bio-markers for cancers and other diseases. The current practice of mass screenings for known tumor markers in high-risk pop-ulations has thus far been the only tool for early diagnosis. However, the specificity and sensitivity of these tumor markers are usually low, which often lead to false positives. Demand to find better methods for early diagnosis of cancers might be met using omics technology platforms, but this technology is still far from exact clinical diagnoses and screenings of high-risk groups. With further development of the three kinds of omics technologies, they will inevitably play an important role in the early diagnosis of cancer.